{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-040851","form_type":"8-K","ticker":"CPHI","cik":"0001106644","company_name":"CHINA PHARMA HOLDINGS, INC.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.304881+00:00","generated_at":"2026-06-02T08:42:00.158429+00:00","sec_items":["4.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"China Pharma terminates auditor BF Borgers after SEC denies its practice privilege; appoints Enrome LLP","bullets":["SEC issued Rule 102(e) Order against BF Borgers CPA PC on May 3, 2024, barring it from appearing or practicing before the SEC as an accountant.","China Pharma terminated Borgers as independent auditor on May 7, 2024, with audit committee approval.","Audit committee engaged Enrome LLP as new independent registered public accounting firm, effective May 7, 2024.","No disagreements or reportable events occurred with Borgers during the past two fiscal years through termination.","Borgers' audit reports for FY2023 and FY2022 contained a going-concern qualification but no adverse opinion."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-040851","json":"https://secwatch.observer/filing/0001213900-24-040851.json","markdown":"https://secwatch.observer/filing/0001213900-24-040851.md","text":"https://secwatch.observer/filing/0001213900-24-040851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1106644/000121390024040851/0001213900-24-040851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1106644/000121390024040851/ea0205550-8k_chinapharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T08:42:00.158429+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"71dc9fd47d8d856045c92952deb72694290889da","claim":"CHINA PHARMA HOLDINGS, INC. dismissed B F Borgers CPA PC as its auditor.","evidence_excerpt":"F Borgers CPA PC (“ Borgers” ), denying its privilege of appearing or practicing before the SEC as an accountant. As a result of the Order, Borgers may not participate in or perform the audit or review of financial information included in the SEC filings, issue audit reports included in the SEC filings, provide consents with respect to audit reports, or otherwise appear or practice before the SEC. On May 7, 2024, China Pharma Holdings, Inc. (the “ Company ”), a corporation incorporated under the laws of the State of Nevada, terminated the engagement with Borgers serving as the Company’s independent registered public accounting firm. The termination of the engagement with Borgers was approved by the Company’s audit committee.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1106644/000121390024040851/0001213900-24-040851-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"B F Borgers CPA PC"},{"label":"Successor","value":"Enrome LLP"}]},{"claim_id":"a32db99b82b907c7fa295ea6b744fbc3ca77e923","claim":"CHINA PHARMA HOLDINGS, INC. engaged Enrome LLP as its auditor.","evidence_excerpt":"udit committee approved the engagement of Enrome LLP (“ Enrome ”) as the Company’s new independent registered public accounting firm.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1106644/000121390024040851/0001213900-24-040851-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Enrome LLP"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}